FIBROGEN INC

Fibrogen Inc.

Biotechnology • Healthcare • San Francisco, CA, United States • FGEN (NMS)

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

415 978 1200 350 Bay Street, San Francisco, CA 94133, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Insider Purchase: CEO of $FGEN Buys 2,700 Shares | FGEN Stock News - Quiver Quantitative
Quiver Quantitative • Nov 17
FibroGen stock rises after roxadustat receives Orphan Drug Designation - Investing.com
Investing.com • Dec 15
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Yahoo Finance • Nov 10
FibroGen shares advance after roxadustat earns orphan drug status - MSN
MSN • Dec 15
FibroGen (NASDAQ: FGEN) gets FDA orphan nod for MDS, on track for Q4 2025 Phase 3 - Stock Titan
Stock Titan • Dec 15

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has FIBROGEN INC had layoffs?
No layoff events have been recorded for FIBROGEN INC in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does FIBROGEN INC have?
FIBROGEN INC has approximately 225 employees.
What industry is FIBROGEN INC in?
FIBROGEN INC operates in the Biotechnology industry, within the Healthcare sector.
Is FIBROGEN INC a publicly traded company?
Yes, FIBROGEN INC is publicly traded under the ticker symbol FGEN on the NMS. The company has a market capitalization of approximately $0.04 billion.
Where is FIBROGEN INC headquartered?
FIBROGEN INC is headquartered in San Francisco, CA, United States at 350 Bay Street, San Francisco, CA 94133, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.